Abahe (Brazilian Association of Hereditary Ataxias) sent a warning message today to the three ministers of the Supreme Federal Court who have not yet expressed their vote regarding RE 1366243, which may restrict judicial access to essential medicines.

Letícia Mota and Suellen Garcia (ABAHE Delegates with Friedreich Ataxia) at the 5th National Conference of Persons with Disabilities.

Biogen CEO Chris Viehbacher, the company's intercontinental director, Fraser Hall, and the Biogen Brazil team met today with Abahe representative Amália Maranhão to hear the story of building the Friedreich's Ataxia community in Brazil.

Pharmaceutical company Biogen has asked Anvisa for a license to register and market in Brazil the first drug for the treatment of the ultra-rare neurodegenerative disease *Friedreich's Ataxia* called Skyclarys.

On February 12, 2024, the European Medicines Agency (EMA) announced that it had approved the drug Skyclarys® (Omaveloxolone) from the pharmaceutical company Biogen for the treatment of Friedreich's ataxia in adults in the countries of the European Union.

VICO Therapeutics, a Dutch company that is testing ASO gene therapy (VO659) for the ataxias SCA1 and SCA3, and also for Huntington's disease (HD), has just announced that it has invested an additional US$60 million to ensure the continuity of research.